Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.
Shaymaa S SeoudiEman A AllamAmal H El-KamelHagar ElkafrawyRiham M El-MoslemanyPublished in: Drug delivery and translational research (2023)
Inflammatory bowel disease (IBD) is characterized by chronic inflammation along the gastrointestinal tract. For IBD effective treatment, developing an orally administered stable drug delivery system capable of targeting inflammation sites is a key challenge. Herein, we report pH responsive hyaluronic (HA) coated Eudragit S100 (ES) nanoparticles (NPs) for the targeted delivery of budesonide (BUD) (HA-BUD-ES-NPs). HA-BUD-ES-NPs showed good colloidal properties (274.8 ± 2.9 nm and - 24.6 ± 2.8 mV) with high entrapment efficiency (98.3 ± 3.41%) and pH-dependent release profile. The negative potential following incubation in simulated gastrointestinal fluids reflected the stability of HA coat. In vitro studies on Caco-2 cells showed HA-BUD-ES-NPs biocompatibility and enhanced cellular uptake and anti-inflammatory effects as shown by the significant reduction in IL-8 and TNF-α. The oral administration of HA-BUD-ES-NPs in an acetic acid induced colitis rat model significantly mitigated the symptoms of IBD, and improved BUD therapeutic efficacy compared to drug suspension. This was proved via the improvement in disease activity index and ulcer score in addition to refined histopathological findings. Also, the assessment of inflammatory markers, epithelial cadherin, and mi-R21 all reflected the higher efficiency of HA-BUD-ES-NPs compared to free drug and uncoated formulation. We thus suggest that HA-BUD-ES-NPs provide a promising drug delivery platform for the management and site specific treatment of IBD.
Keyphrases
- disease activity
- drug delivery
- oxide nanoparticles
- rheumatoid arthritis
- systemic lupus erythematosus
- oxidative stress
- ulcerative colitis
- induced apoptosis
- cancer therapy
- photodynamic therapy
- long non coding rna
- rheumatoid arthritis patients
- depressive symptoms
- ankylosing spondylitis
- high throughput
- physical activity
- cell death
- clinical evaluation